PMID- 25048363 OWN - NLM STAT- MEDLINE DCOM- 20150331 LR - 20211021 IS - 2151-4658 (Electronic) IS - 2151-464X (Print) IS - 2151-464X (Linking) VI - 67 IP - 2 DP - 2015 Feb TI - Mapping of the outcome measures in rheumatology core set for antineutrophil cytoplasmic antibody-associated vasculitis to the International Classification of Function, Disability and Health. PG - 255-63 LID - 10.1002/acr.22414 [doi] AB - OBJECTIVE: The International Classification of Functioning, Disability and Health (ICF) is a framework and classification of health that describes health along 4 components: body functions, body structures, activities and participation, and contextual factors. This study examined the content of instruments that constitute the Outcome Measures in Rheumatology (OMERACT) core set of outcome measures for antineutrophil cytoplasmic antibody-associated vasculitis (AAV) by "mapping" them to the ICF. METHODS: The content of the instruments included in the AAV core set were linked to the ICF by 2 independent investigators according to previously established ICF linkage rules. RESULTS: The AAV core set includes 3 measures of disease activity (3 versions of the Birmingham Vasculitis Activity Score), 1 damage measure (Vasculitis Damage Index), 1 patient-reported outcome (Short Form 36 health survey), and death. Linking these instruments to the ICF revealed comprehensive coverage of the ICF components body functions and body structures, limited coverage of the ICF component activities and participation, and complete absence of coverage of contextual factors. CONCLUSION: ICF was found to be useful for thematic characterization of a heterogeneous group of outcome measures for AAV, i.e., a group of complex medical conditions. Linking of the instruments selected for the OMERACT AAV core set of outcome measures to the ICF classification revealed limitations in the representation of constructs related to life impact of AAV, represented by the ICF components activities and participation and contextual factors. Further research and methods development are needed to better incorporate important aspects of functioning and health relevant to patients into clinical trials of AAV. CI - Copyright (c) 2015 by the American College of Rheumatology. FAU - Milman, Nataliya AU - Milman N AD - Ottawa Hospital and University of Ottawa, Ottawa, Ontario, Canada. FAU - Boonen, Annelies AU - Boonen A FAU - Merkel, Peter A AU - Merkel PA FAU - Tugwell, Peter AU - Tugwell P LA - eng GR - U54 AR-057319/AR/NIAMS NIH HHS/United States GR - U01 AR051874/AR/NIAMS NIH HHS/United States GR - U54-RR-019497/RR/NCRR NIH HHS/United States GR - U54 RR019497/RR/NCRR NIH HHS/United States GR - U01-AR-51874 04/AR/NIAMS NIH HHS/United States GR - U54 AR057319/AR/NIAMS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PL - United States TA - Arthritis Care Res (Hoboken) JT - Arthritis care & research JID - 101518086 SB - IM MH - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/*classification MH - Humans MH - *Outcome Assessment, Health Care MH - *Rheumatology PMC - PMC4505813 MID - NIHMS703984 EDAT- 2014/07/23 06:00 MHDA- 2015/04/01 06:00 PMCR- 2015/08/01 CRDT- 2014/07/23 06:00 PHST- 2014/01/22 00:00 [received] PHST- 2014/07/15 00:00 [accepted] PHST- 2014/07/23 06:00 [entrez] PHST- 2014/07/23 06:00 [pubmed] PHST- 2015/04/01 06:00 [medline] PHST- 2015/08/01 00:00 [pmc-release] AID - 10.1002/acr.22414 [doi] PST - ppublish SO - Arthritis Care Res (Hoboken). 2015 Feb;67(2):255-63. doi: 10.1002/acr.22414.